Insulet (NASDAQ:PODD) Issues Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Insulet (NASDAQ:PODD) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23, FiscalAI reports. The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 earnings per share. Insulet updated its FY 2026 guidance to 6.210- EPS.

Here are the key takeaways from Insulet’s conference call:

• Insulet delivered a strong Q1 with 30% constant-currency revenue growth ($762M, +34% reported), expanded adjusted operating margin +110bps, ~40% adjusted EPS growth, raised full?year revenue guidance to 21–23%, and completed a $300M share repurchase while ending the quarter with $480M cash and full $500M credit availability.
• International momentum remains a key growth driver — 45% constant?currency revenue growth, third consecutive quarter above 40%, broader reimbursement (now 85% of Canada) and planned market/ sensor launches including Spain and FreeStyle Libre 3 Plus in Germany and Canada.
• The product roadmap was emphasized as a catalyst — algorithm enhancements (new 100 mg target estimated to improve time?in?range ~5%), FreeStyle Libre 3 Plus integration, Omnipod 6 with a next?gen algorithm in 2027, and an enrolled pivotal EVOLVE study toward a fully closed?loop type?2 system targeting FDA submission and a 2028 launch.
• Operational and regulatory risk from a voluntary Medical Device Correction (?$12M GAAP charge; >150bps adjusted gross?margin impact from E&O) and an FDA communication about misreported MDRs introduces reputational and regulatory uncertainty, although management says targeted fixes are implemented and no new adverse events have been reported.

Insulet Stock Performance

PODD stock traded down $16.25 during midday trading on Wednesday, hitting $151.28. 4,460,444 shares of the company traded hands, compared to its average volume of 1,123,353. Insulet has a twelve month low of $148.30 and a twelve month high of $354.88. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The business has a 50 day simple moving average of $212.92 and a 200-day simple moving average of $264.96. The stock has a market capitalization of $10.48 billion, a price-to-earnings ratio of 43.22, a price-to-earnings-growth ratio of 0.99 and a beta of 1.20.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and stronger-than-expected revenue: Insulet reported $1.42 EPS and $761.7M revenue (up ~34% YoY), topping estimates and exceeding the high end of its guidance range; management raised the annual revenue-growth outlook on strong Omnipod demand. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Product pipeline progress: Insulet initiated the EVOLVE pivotal study to advance a fully closed?loop automated insulin delivery system, supporting longer?term growth potential for higher?value products. Insulet Initiates EVOLVE Pivotal Study
• Positive Sentiment: Analyst sentiment and technical setup: Some analysts and screens note the stock is technically oversold after recent declines, which could attract buyers if fundamentals remain strong. Insulet (PODD) Loses 17.3% in 4 Weeks
• Neutral Sentiment: Earnings call & transcripts available for detail: Management commentary and the slide deck give more color on margin cadence and the cadence of Omnipod shipments — important for assessing whether the beat is sustainable. Insulet (PODD) Q1 2026 Earnings Transcript
• Negative Sentiment: Guidance nuance: FY 2026 EPS guidance was provided slightly below some consensus figures (management set EPS guidance around 6.21 vs. some street estimates ~6.33), which tempers the upside from the quarter. Insulet Q1 Results & Guidance (MarketBeat)
• Negative Sentiment: Analyst price-target cut: BTIG lowered its price target from $320 to $260 (still a buy), which may signal more conservative near?term expectations and contributed to selling pressure. BTIG Lowers Price Target (Benzinga)

Insider Buying and Selling

In related news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. RTW Investments LP acquired a new position in Insulet during the fourth quarter valued at approximately $92,264,000. AQR Capital Management LLC grew its holdings in Insulet by 161.6% during the fourth quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock valued at $130,499,000 after purchasing an additional 283,643 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new position in Insulet during the second quarter valued at approximately $80,082,000. Squarepoint Ops LLC grew its holdings in Insulet by 11,905.8% during the third quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after purchasing an additional 225,377 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in Insulet by 37.3% during the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after purchasing an additional 156,009 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Leerink Partners cut their price objective on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. JPMorgan Chase & Co. cut their price objective on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a research report on Thursday, February 19th. Canaccord Genuity Group cut their price objective on shares of Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Evercore cut their price objective on shares of Insulet from $340.00 to $240.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Finally, Oppenheimer cut their price objective on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Eighteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $324.38.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.